Gonadorelin

Think of GnRH as a metronome tapping out a beat for the body's hormone orchestra. Gonadorelin is a perfect replica of that metronome. As a real medicine, played at the right tempo through a pump, it can genuinely get a silent orchestra playing again. But the same device left switched on continuously doesn't make louder music; the musicians tune it out and stop entirely. The off-the-shelf vial people inject hoping for a testosterone or libido boost is the right instrument used without the conductor's score: it might do something, it might do the opposite, and almost nobody has actually measured it.

Gonadorelin is identical to natural GnRH. It binds the GnRH receptor on pituitary gonadotrope cells (a Gq-coupled GPCR), driving release of LH and FSH, which then stimulate the gonads to produce testosterone/oestrogen and support gametogenesis. Critically, the effect is frequency-dependent: pulsatile delivery stimulates the axis, while continuous exposure desensitises and suppresses it. It requires a functioning pituitary to work and has a half-life of only a few minutes.

Research contexts. Not proven uses, and not recommendations.

Strong for its licensed roles. As a diagnostic GnRH stimulation test it has decades of clinical use. As pulsatile pump therapy for hypogonadotropic hypogonadism and hypothalamic anovulation it has good controlled human evidence, with ovulation and fertility outcomes broadly comparable to injectable gonadotropins and lower rates of ovarian hyperstimulation and multiple pregnancy in appropriate patients. The use of self-injected gonadorelin as an hCG alternative on TRT, or as a standalone libido enhancer, has essentially no dedicated controlled trial evidence. It is an off-label extrapolation from mechanism, complicated by the very short half-life and the real risk that the wrong delivery rhythm suppresses rather than stimulates the axis.

• !Frequency-dependent paradox: get the rhythm wrong (too frequent or continuous) and it downregulates the receptor and SUPPRESSES the hormone axis. This is the same mechanism used to chemically castrate prostate cancer patients.
• !Very short half-life (minutes) makes naive intermittent self-injection pharmacologically dubious as steady hormone support.
• !Ineffective if the pituitary itself is damaged. It is a pituitary secretagogue, not a direct gonadal stimulator like hCG.
• !Conflated in the wellness market with hCG; the two act at different points in the axis and are not interchangeable.
• !Anaphylaxis and hypersensitivity reactions have been reported with GnRH/gonadorelin administration.
• !Grey-market 'research chemical' vials sold for self-injection carry the usual unlicensed-product risks: no quality control, uncertain purity/sterility, no clinical or pharmacist oversight.
• !No dedicated human trials exist for the libido or TRT-adjunct uses it is most often marketed for.

Gonadorelin is a licensed prescription-only medicine (POM) in the UK. There is an MHRA-authorised product listed on the electronic medicines compendium ('Gonadorelin 100 micrograms powder for solution for injection') used for the diagnostic GnRH stimulation test of pituitary gonadotroph function. Pulsatile pump formulations (e.g. Lutrelef/Lutrepulse, Ferring) have been used for hypogonadotropic infertility, although the availability of specific brands has varied over time and some have been discontinued for commercial reasons. As a regulated medicine it is intended to be prescribed and supervised by a clinician. Separately, gonadorelin is widely sold online by 'research chemical' suppliers labelled 'not for human consumption'; supplying or self-administering such unlicensed product outside the regulated medicines framework sits outside MHRA authorisation and carries the legal and safety risks of any unlicensed injectable.

• NCT01976728· Phase 3· Completed

  Pulsatile subcutaneous GnRH (gonadorelin) via pump for ovulation induction in women with hypogonadotropic hypogonadism / primary amenorrhoea (Ferring programme)

  Randomised, placebo-controlled study of pulsatile gonadorelin (FE 999037/FE 999903) delivered by wearable pump for ovulation induction.

1. 01
   FACTREL (gonadorelin hydrochloride) for injection — US prescribing information / FDA label, DailyMed / FDA (NDA 017866)

   Approved diagnostic indication: evaluation of the functional capacity and response of the anterior pituitary gonadotropes.

2. 02
   Gonadorelin 100 micrograms powder for solution for injection — Summary of Product Characteristics (SmPC), electronic medicines compendium (emc), UK

   UK MHRA-licensed POM; confirms prescription status and the diagnostic pituitary-test indication.

3. 03
   Belchetz PE et al. Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone, Science (1978)

   Landmark demonstration that pulsatile GnRH stimulates gonadotropin secretion while continuous exposure desensitises it.

4. 04
   Pulsatile gonadotrophin-releasing hormone for ovulation induction in subfertility (Cochrane systematic reviews), Cochrane Database of Systematic Reviews

   Cochrane evidence base for pulsatile GnRH in ovulation induction; PubMed search rather than a single fixed identifier as the relevant reviews span several updates and indications.